Sweden’s Xbrane Lays Out Ranibizumab Ambitions

As Key Biosimilar Trial Affected By COVID-19

 
• By Dean Rudge
  
Eye
Xbrane is eyeing the considerable size of the anti-VEGF market for its biosimilar ranibizumab candidate • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products